De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times? The bone-modifying agents zoledronic acid, pamidronate, and denosumab have essential ...
Significant unmet needs in SMA management include therapy access, fatigue, reproductive health, and emerging phenotypes in older patients. Intrathecal gene therapy offers potential for older SMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results